Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Fellowship - CIHR/Rx&D - Wyeth Pharmaceuticals Research Program

University of British Columbia

$22,500.00

Immunomodulatory Approches to Dealing with Infection

EF 2008-09

Résumé
We have been developing novel therapeutic strategies against infections based on the selective modulation of innate immunity (Nature Biotech. 25: 465-472, 2007). To identify further ways of productively modulating the human innate host defence system, we propose to study the impact of several diseases on innate immunity, including (1) monogenic human genetic diseases including Interleukin Receptor Associated Kinase 4 (IRAK4) deficiency and cystic fibrosis (CF), and (2) inflammatory bowel disease. Mice with defined mutations, received by our lab from our collaborator the Sanger Wellcome Centre in England (Gordon Dougan) as part of a large Genome Canada funded program, will be also utilized to obtain insight into both the mechanisms of perturbation of innate immunity and the mechanism of activity of our IDR therapeutic peptides. In particular we will use systems biology approaches and a series of novel bioinformatics tools, Innate DB, and Cerebral, to interrogate the pathway defects and sufficiencies in these situations. The ability of our current immunomodulatory peptides to at least partially reverse the immune defect in the patients will be studied and we will exploit the knowledge gained from these clinical situations and mice to design novel targets and small molecular therapeutic agents.
Programme
Fellowship - CIHR/Rx&D - Wyeth Pharmaceuticals Research Program
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
174374
Name
Ma Shuhua
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Wyeth Pharmaceuticals
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Industry Partnered Collaborative Research
Projecttitle
Immunomodulatory Approches to Dealing with Infection
Programtype2
Fellowship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$22,500
Cihrequipment2
$0
Programname2
Fellowship - CIHR/Rx&D - Wyeth Pharmaceuticals Research Program
Keyworddelim
Functional Genomics; Genetic Diseases; Infection; Inflammation; Peptides; Therapy
Abstract
We have been developing novel therapeutic strategies against infections based on the selective modulation of innate immunity (Nature Biotech. 25: 465-472, 2007). To identify further ways of productively modulating the human innate host defence system, we propose to study the impact of several diseases on innate immunity, including (1) monogenic human genetic diseases including Interleukin Receptor Associated Kinase 4 (IRAK4) deficiency and cystic fibrosis (CF), and (2) inflammatory bowel disease. Mice with defined mutations, received by our lab from our collaborator the Sanger Wellcome Centre in England (Gordon Dougan) as part of a large Genome Canada funded program, will be also utilized to obtain insight into both the mechanisms of perturbation of innate immunity and the mechanism of activity of our IDR therapeutic peptides. In particular we will use systems biology approaches and a series of novel bioinformatics tools, Innate DB, and Cerebral, to interrogate the pathway defects and sufficiencies in these situations. The ability of our current immunomodulatory peptides to at least partially reverse the immune defect in the patients will be studied and we will exploit the knowledge gained from these clinical situations and mice to design novel targets and small molecular therapeutic agents.
Competitiondate
200810
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ma, Shuhua
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $22,500~ $0~